Daniel Corina

ABSTRACT

Albuminuria is widely recognized as an important indicator of kidney damage and is routinely used to evaluate disease severity and progression in individuals with chronic kidney disease (CKD). Because alterations in urinary albumin excretion often occur before irreversible loss of kidney function, changes in albuminuria have been proposed as an early surrogate endpoint in clinical trials investigating CKD therapies. However, confirmation of its predictive value across different patient populations and treatment strategies remains essential.